This was the stock's fifth consecutive day of losses.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Now, it’s worth noting Stock Advisor’s total average return is 1,039% — a market-crushing outperformance compared to 182 % for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol-Myers Squibb Company (NYSE:BMY) is scheduled to announce Q2 earnings results on July 31st, before markets open.

Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...